Omeros Co. (NASDAQ:OMER) CAO Michael A. Jacobsen sold 10,000 shares of the stock in a transaction on Friday, February 19th. The stock was sold at an average price of $22.64, for a total value of $226,400.00. Following the completion of the transaction, the chief accounting officer now owns 24,000 shares of the company’s stock, valued at approximately $543,360. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Omeros stock traded down $0.52 during trading hours on Tuesday, hitting $22.15. The stock had a trading volume of 665,375 shares, compared to its average volume of 829,944. The stock has a market capitalization of $1.37 billion, a price-to-earnings ratio of -9.30 and a beta of 1.65. Omeros Co. has a 1-year low of $8.50 and a 1-year high of $25.46. The stock’s fifty day moving average is $19.52 and its two-hundred day moving average is $14.03.
Several research analysts have issued reports on OMER shares. Maxim Group increased their price objective on Omeros from $20.00 to $25.00 and gave the stock a “buy” rating in a research report on Friday, December 4th. HC Wainwright increased their price objective on Omeros from $31.00 to $34.00 and gave the stock a “buy” rating in a research report on Wednesday, January 20th. Zacks Investment Research cut Omeros from a “buy” rating to a “hold” rating in a research report on Friday, November 20th. Finally, UBS Group started coverage on Omeros in a report on Monday, February 1st. They issued a “buy” rating and a $25.00 target price on the stock. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Omeros presently has an average rating of “Buy” and an average target price of $22.00.
A number of institutional investors have recently bought and sold shares of OMER. Sonora Investment Management LLC acquired a new stake in shares of Omeros during the third quarter valued at $36,000. Fifth Third Bancorp boosted its stake in shares of Omeros by 39.2% during the third quarter. Fifth Third Bancorp now owns 3,550 shares of the biopharmaceutical company’s stock valued at $36,000 after acquiring an additional 1,000 shares during the last quarter. Freestone Capital Holdings LLC acquired a new stake in shares of Omeros during the third quarter valued at $37,000. GWM Advisors LLC acquired a new stake in shares of Omeros during the third quarter valued at $105,000. Finally, DekaBank Deutsche Girozentrale acquired a new stake in shares of Omeros during the third quarter valued at $138,000. 56.63% of the stock is currently owned by institutional investors.
Omeros Company Profile
Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.
Featured Article: Understanding Average Daily Trade Volume
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.